Synairgen plc
('Synairgen' or the 'Company')
Result of General Meeting and Total Voting
Rights
Southampton, UK -
16 January 2025: Synairgen
plc (LSE: SNG), the respiratory company developing SNG001, an
investigational formulation for inhalation containing the
broad-spectrum antiviral protein interferon beta,
announces that, at the General Meeting held
earlier today, all resolutions as set out in the Circular dated 20
December 2024, were duly passed by shareholders on a
poll.
A summary of the votes received for
the General Meeting will be made available shortly on the Company's
website at https://www.synairgen.com/investors/aim-rule-26.
Accordingly, the Company has raised
total gross proceeds of £18 million from the Subscription by TFG
Asset Management (on behalf of the Relevant Funds).
Application has been made for a
total of 900,000,000 New Ordinary Shares to be issued pursuant to
the Subscription, to be admitted to trading on AIM. It is
expected that Admission and dealings in the 900,000,000 New
Ordinary Shares will commence at 8.00 a.m. on 17 January
2025.
Following Admission, the Company's
issued ordinary share capital will comprise 1,102,660,697 Ordinary
Shares, none of which are held in treasury. The above figure of
1,102,660,697 may be used by Shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in, the
voting rights of the Company under the FCA's Disclosure Guidance
and Transparency Rules.
As detailed in the Results of
Non-Underwritten Fundraising announcement on 15 January 2025, as
the Minimum Fundraising Condition was not met the Company intends
to apply for the cancellation of its Ordinary Shares from trading
on AIM ("Cancellation"). A separate announcement will be made in
this regard and a circular will be posted to Shareholders in due
course which will contain details of the proposed
Cancellation.
Following the conclusion of the
General Meeting, Martin Murphy has been appointed as an independent
Non-Executive Director of the Company. See separate announcement
issued today announcing Martin's appointment.
This announcement should be read in
conjunction with the full text of the Circular posted to
Shareholders on 20 December 2024, copies of which are available on
the Company's website. The same definitions apply throughout this
announcement as are applied in the Circular.
For
further enquiries, please contact:
|
Synairgen plc
|
+ 44 (0)23 8051 2800
|
|
Media@synairgen.com
|
|
|
Cavendish Capital Markets Limited -
Nominated Adviser, joint broker and sole
bookrunner
|
+ 44 (0)20 7220 0500
|
|
Geoff Nash/Camilla Hume/Trisyia
Jamaludin
|
|
|
ICR
Healthcare (Financial Media and Investor
Relations)
|
+44 (0)20 3709 5700
|
|
Mary-Jane Elliott/Namrata Taak/Lucy
Featherstone
synairgen@icrhealthcare.com
|
|
Notes for
Editors
About Synairgen
Synairgen is a UK-based respiratory
company focused on drug discovery and the development of SNG001
(inhaled interferon beta) as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the
lungs for severe viral lung infections.
Millions of people globally are
hospitalised every year due to viral lung infections and there are
currently no approved antiviral therapies for the majority of these
patients. Synairgen is developing SNG001 to address this
need.
Synairgen is quoted on AIM (LSE:
SNG). For more information about Synairgen, please see
www.synairgen.com
The information contained within this announcement is deemed
to constitute inside information as stipulated under the retained
EU law version of the Market Abuse Regulation (EU) No. 596/2014
(the "UK MAR") which is part of UK law by virtue of the European
Union (Withdrawal) Act 2018.
